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Objective: Recent studies have shown abnormal expression of CD44s and some of its isoforms in many
human malignancies, but little is known about the presence of CD44 in chondrosarcoma. In this study
the expression of CD44s and two variant isoforms was evaluated. It was assumed that abnormalities in
these receptor proteins may be associated with clinical outcome of the patients.
Method: Thirty parafﬁn-embedded chondrosarcoma samples were immunostained with monoclonal
antibodies for CD44s, CD44v5 and CD44v6. Two independent examiners who were unaware of the
clinical status of the patients evaluated the immunohistochemical results. The percentage of CD44-
positive cells was scored semiquantitatively. A rate of higher than 10% was considered as overexpression.
Results: Among the 30 patients (median age 50 years) there were 22 conventional chondrosarcomas, two
dedifferentiated chondrosarcomas, two extraskeletal chondrosarcomas, and one periostal, mesenchymal,
clear cell and myxoid chondrosarcoma each. In the immunochemistry staining overexpression (>10% of
cells) of CD44s was shown in 56.7% (17 of 30), of CD44v5 in 43.3% (13 of 30) and of CD44v6 in 6.7% (two
of 30) of the tumors. Four grade III chondrosarcomas (80%) and 10 (71.4%) grade II chondrosarcomas
showed overexpression for CD44s, whereas CD44s was overexpressed in only three (27.3%) grade I
chondrosarcomas. Cox regression suggests overexpression of CD44s to be an additional prognostic
marker for chondroid bone tumors independent of grading and other covariates.
Conclusions: Overexpression of CD44s correlated signiﬁcantly with metastatic potential and with poorer
survival in patients with chondrosarcoma. CD44s might be an independent additional marker, but small
sample size remains to be considered.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.3,5Introduction
Amongst all malignant bone tumors chondrosarcoma is the
second most common, accounting for 10e26% of all osseous
malignancies1e3. It is the most frequently diagnosed bone tumor in
the population older than 50 years1,3. The most common skeletal
sites affected by chondrosarcoma are the bones of the pelvis
followed by the proximal femur, proximal humerus, distal femur
and ribs1. Clinical symptoms are very unspeciﬁc. Radiographic
ﬁndings often suggest the diagnosis of chondrosarcoma because of
identiﬁcation of typical “ring-and-arc” chondroid matrix mineral-
ization and aggressive features of deep endosteal scalloping and
soft tissue extension4. Chondrosarcomas range from locally
aggressive tumors with almost no metastatic potential to high-Thomas J. Heyse, University
umatology, Baldingerstrasse,
ax: 49-6421-58-67-007.
eyse).
s Research Society International. Pgrade malignancies with a marked propensity to metastasize .
Based on nuclear atypia and cellularity chondrosarcomas are clas-
siﬁed into three grades1. Low-grade chondrosarcomas (grade I)
grow slowly and are associated with a very low rate of metastasis
and death. On the other hand, high-grade tumors (grade II or III)
grow more aggressively and metastasis occurs more frequently,
which correlates with poorer survivorship5,6.
CD44 is a transmembrane glycoprotein belonging to the family
of cell adhesion proteins. CD44 is present on the surface of many
vertebrate cells, such as chondrocytes, lymphocytes, many types of
epithelial cells, ﬁbroblasts, smoothmuscle cells and a subset of glial
cells in the central nervous system7.
The human CD44 gene is encoded by a single, highly conserved
gene with a length of 50e60 kb and is composed of 20 exons8,9.
CD44 can be expressed in many isoforms. The ﬁve amino-terminal
exons and ﬁve carboxy-terminal exons code together the standard
CD44 protein (CD44s), which has a molecular weight of
85e95 kDa9. It is the most broadly expressed CD44 form10. By
alternative splicing additional variable exons can be inserted intoublished by Elsevier Ltd. All rights reserved.
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cule producing CD44 isoforms9. The heterogeneity of the CD44
isoforms is also partially generated by posttranslational, cell-type
dependent glycosylation and glycosaminoglycan addition10.
The most important function attributed to CD44 is to promote
cellecell and cellematrix attachment, mostly through interactions
with hyaluronic acid11,12. CD44s has essential functions in
lymphocyte adhesion and migration, T-cell differentiation, cell
proliferation but also in cell-apoptosis signaling13,14. The functions
of CD44 variants are less well known. The involvement of CD44v6
in supporting maturation and expansion of hematopoietic
progenitor cells was described15.
Of large importance is the participation of CD44 in tumor
growth, invasion and metastasis development. Some CD44 variants
in a rat model (homologous to human v6 isoform) are expressed
only in cell lines of pancreatic carcinoma and mammary adeno-
carcinoma that developed metastasis. Moreover, the injection of
transfectants that express both CD44 and CD44v6 into non-meta-
stazing tumor cell lines conferred metastatic behavior16.
Manyother studies show the associationbetween extent of CD44
expression with tumor growth and more aggressive behavior in
human neoplasms, such as prostate cancer, uterine cervical cancer,
gastric carcinoma, breast cancer, lung neoplasms, malignant
lymphomas, colon carcinoma, some brain tumors or soft tissue
sarcomas17e28 Overexpression of CD44v5 may play a role in meta-
static behavior of some musculoskeletal malignancies, as in
osteosarcoma29,30. There are reports suggesting that differential
CD44v6 expression in chondrosarcoma is associatedwithmalignant
transformation31. However, in patients with chondrosarcoma, the
degree of CD44 expression and its prognostic value have not been
reported.
In the present study, the expression proﬁles of CD44s as well
as CD44v5 and CD44v6 isoforms were investigated usingFig. 1. Grade I chondrosarcomas are composed of moderately cellular mass (aed). The cells
shows increased cellularity (eeh). The nuclei are enlarged, hyperchromatic and atypic. The
than Grade II. Mitotic ﬁgures are common. The intercellular spaces are ﬁlled with myxoid m
(HE) staining. The second column shows CD44s, the third column CD44v5 and the forth co
overexpression with >10% of positive cells is shown. In g, h and l expression of CD44 isofoimmunohistochemical staining in chondrosarcoma specimens
from 30 patients. Staining results were correlatedwith pathological
and clinical parameters to estimate its prognostic effect.
Method
Tumor samples
The pathology ﬁles of 36 patients with chondrosarcoma who
had been diagnosed and treated in the authors' institution were
retrospectively explored. Thirty patients whose tissues were
available were included into this study. 14 patients were males and
16 were females. The median age was 50 (range, 13e82) years. The
median follow-up period was 62.5 (range: 0e233; mean
85.8 19.5) months. The tumors were located in axial skeleton in
18 cases [pelvis (8); vertebra (4); shoulder, (4); thorax (2)] and in
the limbs in 10 cases [femur (7); ﬁbula, (1); cuboid (1); and
metatarsal (1)]. Two tumors were located extraskeletal. There were
22 patients classiﬁed as having conventional chondrosarcomas,
two patients as having dedifferentiated chondrosarcomas, two
patients as having extraskeletal chondrosarcomas, and each one
patient as having periostal, mesenchymal, clear cell and myxoid
chondrosarcoma. There were 11 grade I (36.7%), 14 grade II (46.7%)
and ﬁve grade III chondrosarcomas (16.6%).
The most common treatment was the surgical resection of the
tumors in 26 cases. Two patients underwent radiotherapy (one
combined with chemotherapy). One patient was treated with
radiotherapy after undergoing intralesional resection. Preoperative
chemotherapy was performed in two patients and one patient
received postoperative chemotherapy. Because of co-morbidity two
patients received no therapeutic treatment at all.
R1 was deﬁned as tumor resection margins detectable micro-
scopically, and R2 as macroscopically detectable residual tumor. R0contain small dense nuclei, uniform in size. The stroma is mostly chondroid. Grade II
stroma is frequently myxoid. Grade III tumors (ie l) are more cellular and pleomorphic
aterial. The ﬁrst column shows chondrosarcoma Grades IeIII in hematoxilin and eosin
lumn CD44v6. Positive cells are stained brown mostly at the cell membrane. In f and j
rms is shown, in these examples* with <10% of positive cells.
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the resection margin. The grading of all tumors was reviewed by
the time of the study (RM). Reference pathology from other insti-
tutions was obtained. Tumors were categorized as small when they
were smaller than 8 cm in diameter. When they were larger than
8 cm in at least one dimension they were considered as large
tumors.
Sixteen patients had local recurrences (53.3%). Metastasis
developed in 12 patients (40%), including four patients with known
metastases at the time of diagnosis. The metastases were treated in
three cases with surgery only, in three cases with surgery combined
with adjuvant treatments and in one case with chemotherapy only.Immunohistochemical staining and staining analysis
The selected, parafﬁn-embedded tissues were immunostained
with mouse monoclonal antibodies against CD44s (Clone: SFF-2,
dilution 1:10 000), CD44v5 (Clone: VFF-8, dilution 1:500) and
CD44v6 (Clone: VFF-18, dilution 1:8000), all from Bender
MedSystems. The sections were dewaxed by xylene rinsing and
rehydrated gradually through graded alcohols. The slides were
rinsed with distilled water and placed in a jar with a 1:10 diluted
Dako Target Retrieval Solution buffer (S 1699) at a pH of 6.1 (Dako).
The jar was heated in a steamer for 30 min. After cooling and
rinsing with distilled water and Dako S 3006 buffer, the slides were
placed in a Dako Autostainer plus immunostaining system.
Immunostaining was performed using a labeled streptavi-
dinebiotin method (Dako REAL Detection System Peroxidase/
DABþ), the staining reaction being based on 3,3'-diaminobenzidine
(DAB). The stained slides were rinsed with distilled water and
stained for 5 min with hemalaun as counterstain. Finally, the
sections were rinsed with water and treated with graduated-Table I
Patient characteristics
No. Sex Age at
diagnosis
Histology of
chondrosarcoma
Grading Localization Therapy
1 Female 55 Conventional Grade I Femur Surgery
2 Male 27 Conventional Grade I Pelvis Surgery
3 Male 67 Conventional Grade I Pelvis None
4 Male 75 Conventional Grade II Pelvis Surgery
5 Male 33 Conventional Grade II Fibula Surgery
6 Female 26 Conventional Grade I Spine Surgery
7 Female 50 Conventional Grade III Shoulder Surgeryþ chemothe
8 Male 75 Conventional Grade II Spine Radiotherapyþ
chemotherapy
9 Male 36 Conventional Grade I Spine Surgery
10 Female 37 Conventional Grade I Pelvis Surgery
11 Male 66 Dedifferentiated Grade III Femur Surgery
12 Female 72 Conventional Grade II Pelvis Surgery
13 Male 52 Conventional Grade II Shoulder Surgery
14 Female 82 Conventional Grade I Pelvis Radiotherapy
15 Male 37 Conventional Grade II Pelvis Surgery
16 Female 62 Clear-cell Grade II Femur Surgery
17 Female 50 Conventional Grade II Foot Surgery
18 Female 15 Conventional Grade I Shoulder Surgery
19 Female 72 Dedifferentiated Grade III Femur None
20 Male 38 Conventional Grade II Foot Surgery
21 Male 36 Conventional Grade I Spine Surgery
22 Female 61 Extraskeletal Grade II Extraskeletal Surgeryþ chemothe
23 Male 74 Extraskeletal Grade III Extraskeletal Surgery
24 Male 45 Conventional Grade I Shoulder Surgery
25 Female 44 Conventional Grade II Thorax Surgery
26 Female 33 Periosteal Grade II Thorax Surgery
27 Female 37 Conventional Grade I Femur Surgery
28 Female 51 Conventional Grade II Femur Surgery
29 Male 82 Myxoid Grade II Femur Surgeryþ radiothera
30 Female 13 Mesenchymal Grade III Pelvis Surgeryþ chemothedensity alcohol and with xylol. As positive controls skin tissues
were used.
The immunohistochemical results were evaluated by two
independent investigators who were blinded to the clinical
information. The mean values of their results were used as basis for
following calculations. The Cornbach alpha averaged 0.979 for
CD44s, 0.946 for CD44v5 and 0.751 for CD44v6 indicating a high
interobserver reliability. The percentage of CD44-positive cells was
scored semiquantitatively as: negative when there were less than
10% of positive cells, and overexpression when there were more
than 10% of positive cells according to Endo et al.32.
Statistical analysis
The data were analyzed with SPSS analytic software.
KaplaneMeier method was used to estimate the survival. Survival
functions were compared by using the Logrank test. To determine
whether CD44 stainings are new independent prognostic variables,
a multivariate analysis with grading, resection margins, sex, age,
tumor size and location (trunk vs extremities) as covariates, a Cox
regression (Wald test) was performed. Results were expressed as
hazard ratios with conﬁdence intervals. High hazard ratios reﬂect
a high impact of the parameter. For all tests, P< 0.05 was consid-
ered to be statistically signiﬁcant.
Results
CD44s was expressed in 73.3%, CD44v5 in 80.0% and CD44v6 in
33.3% of the tumors (Fig. 1) including also specimen with <10%
positive cells. 56.7% of the chondrosarcoma showed overexpression
of CD44s with >10% positive cells. Overexpression of CD44v5 was
shown in 43.3% of the cases and overexpression of CD44v6 wasResection
margins
Recurrence Metastasis Metastasis free
survival time
Death Survival time/
observance time
(months)
R0 Yes Yes 42 Yes 55
R2 Yes 0 Yes 6
No Op Yes 12
R0 Yes Yes 63 Yes 74
R0 Yes 85
R0 Yes 233
rapy R0 Yes Yes 0 Yes 28
No Op 83
R0 Yes 101
R0 Yes 161
R0 Yes Yes 2 Yes 5
R1 0
R1 Yes Yes 78 186
No Op Yes 43
R0 Yes Yes 2 Yes 179
R2 Yes 97
R0 Yes Yes 23 25
R0 Yes 182
No Op Yes 0 Yes 4
R0 129
R0 Yes Yes 66 Yes 66
rapy R0 217
R0 Yes Yes 39 Yes 57
R0 214
R0 38
R0 Yes 59
R0 205
R0 1
py R2 Yes 2
rapy R0 Yes 0 27
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cell membrane of tumor cells. The CD44 expression was not age or
sex dependent (Table I).
Association of overexpression of CD44 isoforms with
clinicopathologic characteristics
KaplaneMeier analysis showed that overexpression of CD44s
was associated with decreased metastatic free survival time of
chondrosarcoma (P< 0.01, Fig. 2) In addition, in survival analysis
patients with chondrosarcoma that expressed CD44s in>10% of the
cells had a signiﬁcantly shorter survival time (average: 110 months
vs 194 months; P< 0.01, Fig. 3).Fig. 2. Cumulative metastasis free survival (KaplaneMeier) in dependence of expression of
the survival for patients positive for the respective CD44 isoform.Cox regression revealed that the variable overexpression CD44s
was independent from the variable grading and all other applied
covariates for survival (hazard ratio 46.70 and P¼ 0.0074, Table II)
and metastasis (hazard ratio¼ 78.87, P¼ 0.021, Table III).
Overexpression of CD44v5 was not associated with either the
appearance of metastasis (P¼ 0.77) and poorer survival in patients
(P¼ 0.55) with chondrosarcoma in the KaplaneMeier analysis
(Figs. 2 and 3). In Cox regression, overexpression of CD44v5was not
found to be an independent prognostic variable for survival (hazard
ratio¼ 10.48, P¼ 0.14, Table II). Cox regression showed, however,
that it may be an independent prognostic marker for metastasis
(hazard ratio¼ 100.82, P¼ 0.045, Table III). Thus, the statistical
ﬁndings for CD44v5 are inconsistent.CD44s and CD44v5: blue graphs indicate CD44 negative patients. Green graphs outline
Fig. 3. Cumulative survival in dependence of expression of CD44s and CD44v5 (KaplaneMeier): blue graphs indicate CD44 negative patients. Green graphs outline the survival for
patients positive for the respective CD44 isoform.
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a KaplaneMeier analysis was not performed for this subgroup. In
the Cox regression, CD44v6 was not found to be an independent
variable for neither survival (hazard ratio¼ 0.24, P¼ 0.42) nor
metastasis (hazard ratio¼ 0.71, P¼ 0.83).
Discussion
There are many studies describing the presence of CD44 and its
isoforms (especially CD44v5 and CD44v6) in normal and degen-
erative cartilage cells33e36. In cartilage, the hyaluronic acid receptor
plays an important role in cell attachment to the extracellularmatrix. Moreover, CD44 affects the metabolism and proliferation of
cartilage cells37,38. Other studies characterize the role of CD44 in
tumor growth and metastasis development in cartilage. Ishida et al.
showed that CD44 may play an important role in normal and
abnormal functions in cartilaginous cells through its adhesion
to hyaluronic acids. In their study, chondrosarcoma-derived
chondrocyte-like cell-line HCS-2/8 effectively adhered to hyaluronic
acids through cell surface CD44. The adhesion was also involved in
cellular signaling, which induced proliferation and expression of
c-myc mRNA as well as TGF-beta mRNA expression within the
cells39. On the other hand treatment with CD44 monoclonal anti-
bodies in human chondrosarcoma cell lines reduced the cell
Table II
Results of a Cox regression for survival considering overexpression of CD44 isoforms,
grading and risk factors: results were expressed as hazard ratios with conﬁdence
intervals and P-values from Wald test (*likelihood-ratio test). High hazard ratios
reﬂect an increased risk
Death Hazard
ratios
95% Conﬁdence
interval
P-values
CD44s positive 46.70 2.81e777.64 0.0074
CD44v5 pos. 10.48 0.48e230.80 0.14
CD44v6 pos. 0.24 0.008e7.35 0.42
Grading GII vs GI 0.004 0.00002e0.86 0.044
Grading GIII vs GI 15.24 0.29e792.62 0.18
R0 0.42 0.009e19.28 0.65
R1 and R2 8.49 0.14e521.26 0.31
Female sex 1.29 0.29e55.94 0.32
Age at diagnosis 1.07 0.95e1.20 0.26
Location at extremity vs trunk 0.92 0.04e21.19 0.96
Tumor size> 8 cm 10.38 0.57e188.16 0.11
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mentation and apoptotic body formation40. Another study showed,
that CD44 stimulation facilitates invasion of chondrosarcoma
cells41. Cartilaginous CD44 takes active part in tumor origin and
dissemination but to date, there is little known about the correla-
tion between the CD44 expression and clinical outcome of patients
with chondrosarcoma. The most valuable predictor of patients'
outcome at this time is the histological grade6,42.
To our knowledge this study is the ﬁrst to investigate the
expression of CD44 in chondrosarcomas in correlation with clinical
outcome. The most important ﬁnding of the current study is the
prognostic signiﬁcance of the expression of CD44s in malignant
cartilaginous tumors. Cox regression revealed that CD44s is
a signiﬁcant variable independent from grading with respect to
survival and metastasis. Cox regression showed that over-
expression of CD44v5 may be an independent prognostic marker
for metastasis but not for survival. This was not supported by
results of the KaplaneMeier analysis for CD44v5 and statistical
tests remain inconsistent concerning this subtype.
CD44s and maybe also CD44v5 could be useful as prognosis
predictor in malignant cartilaginous tumors. However, there are
some limitations to these statements due to sample size. The
results have to be handled with care. Early excitement over the
prognostic value of CD44 isoforms in breast cancer turned out to be
substantially less useful when larger studies were performed43,44.
Another limitation to the study is that grading of chondrosarcoma
remains somewhat subjective in dependence of the examining
pathologist. Biopsies from large tumors might be prone to sampling
bias. Some of the histologically diagnosed G1 tumors that devel-
oped metastasis might eventually have been or progressed to
higher grade tumors.
This analysis contains all histological subtypes of
chondrosarcoma. They have in common that they are malignanciesTable III
Results of a Cox regression for metastasis analog to Table II
Metastasis Hazard
ratios
95% Conﬁdence
interval
P-values
CD44s positive 78.87 1.92e3242.97 0.021
CD44v5 pos. 100.82 1.11e9179.81 0.045
CD44v6 pos. 0.71 0.03e18.01 0.83
Grading G2 vs G1 0.05 0.002e1.21 0.065
Grading G3 vs G1 267.25 5.10e13993.19 0.0057
R0 0.54 0.008e34.32 0.77
R1 and R2 12.03 0.20e723.04 0.23
Female sex 7.65 0.61e95.65 0.11
Age at diagnosis 0.98 0.92e1.04 0.43
Location at extremity vs trunk 2.15 0.19e24.24 0.53
Tumor size> 8 cm 45.34 1.23e1673.45 0.038producing chondroid matrix, which justiﬁes putting them together.
Limiting the analysis to conventional chondrosarcomas would still
come with a large degree of heterogeneity among the cases, since
already these are morphologically and clinically very diverse.
These data support the thesis that CD44s expression is related to
metastatic potential and patients' outcome in some tumors.
Bhatavdekar et al. showed in a multivariate analysis that CD44
overexpression was the most important indicator of an unfavorable
prognosis for overall survival inpatientswith colorectal carcinoma45.
Strong CD44 expressionwas associatedwith shorter 10-year survival
rate among patients with gastrointestinal lymphoma22. Also in
bladder cancer association between strong expression of CD44s and
unfavorable outcome was found. Moreover, the expression intensity
of CD44s was signiﬁcantly related to pathological grading of bladder
cancer46. However, increased levels of CD44 expression not neces-
sarily correlates with poor prognosis in every malignancy. In some
tumors, cases with low CD44 expression demonstrate higher meta-
static potential than cases with high CD44 expression47,48.
Also CD44v6 seems to be important formalignancies to generate
more aggressive growth and potential for metastasis. CD44 variants
containing exon v6 sequences appeared mostly at the advanced
stage of tumor development andweremore prevalent inmetastatic
colorectal carcinomas28. Elevated levels of CD44v6 expressionwere
observed in disseminated large-cell lymphomas49. Patients with
primary breast cancer who expressed CD44 with v6 epitope had
a poor overall survival compared to patients with v6 negative
tumors43. Bosch et al. postulated that CD44v6 may play a role in
origin of abnormal cartilage phenotype. In their study the presence
of ﬁbrocartilaginous neoplastic masses was associated with lack of
the CD44 variant containing v631. However, only three low-grade
chondrosarcomas were included in their work and no correlation
betweenpatients' prognosis and CD44 stainingwas provided. In the
presented data, there were only little numbers of tumors and cells
staining positive for CD44v6 and only two tumors met the criteria
for overexpression. Thus, no signiﬁcant ﬁndings for overexpression
of v6 were found.
As these data demonstrated, CD44 may play a crucial role in
growth and dissemination inmany human tumors. It is hypothesized
that the expression of CD44 and CD44v5 could contribute to invasive
growing and developing of metastasis in chondrosarcoma, too.
We assume that a simple immunohistochemical staining of chon-
drosarcoma samples with CD44s and CD44v5 could help with
grading of chondrosarcoma and prognosis of disease. Power of this
study is limitedbysample sizeand theheterogeneityof appearanceof
chondrosarcoma. Thismight also affect the results of themultivariate
analysis performed and might explain why some of the known
negative predictors for survival and metastasis in chondrosarcoma
failed statistical signiﬁcance in the presented setting. However, Cox
regression and KaplaneMeier analysis suggested that CD44s may be
a prognostic variable independent from grading and the other
included covariates with respect to survival and metastasis.Conclusion
In conclusion, positive cell staining for CD44s was signiﬁcantly
associated with the metastatic potential and survival in patients
with chondrosarcoma. The results of this study demonstrate that
CD44s could be an additional independent prognostic marker for
patients with chondrosarcoma.
Conﬂict of interest
All authors declare to have nothing to disclose and to have no
potential conﬂict of interest that could inappropriately inﬂuence
the presented work.
T.J. Heyse et al. / Osteoarthritis and Cartilage 18 (2010) 849e856 855Acknowledgments
The authors would like to thank Renate Baumann from the
Institute of Pathology, Marburg, Germany for her support.
References
1. Fletcher CDM, Krishnan Unni K, Mertens F. Pathology and
genetics of tumors of soft tissue and bone e chondrosarkoma,
2002.
2. Schajowicz F. Tumors and Tumor like Lesions of Bone. New
York: Springer; 1994
3. Dorfman HD, Czerniak B. Bone cancers. Cancer 1995 Jan 1;75
(1 Suppl):203e10.
4. Murphey MD, Walker EA, Wilson AJ, Kransdorf MJ, Temple HT,
Gannon FH. From the archives of the AFIP: imaging of primary
chondrosarcoma: radiologicepathologic correlation. Radio-
graphics 2003 SepeOct;23(5):1245e78.
5. Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in
chondrosarcoma of bone: a clinicopathologic analysis with
emphasis on histologic grading. Cancer 1977 Aug;40
(2):818e31.
6. Lee FY, Mankin HJ, Fondren G, Gebhardt MC, Springﬁeld DS,
Rosenberg AE, et al. Chondrosarcoma of bone: an assessment
of outcome. J Bone Joint Surg Am 1999 Mar;81(3):326e38.
7. Picker LJ, Nakache M, Butcher EC. Monoclonal antibodies to
human lymphocyte homing receptors deﬁne a novel class of
adhesion molecules on diverse cell types. J Cell Biol 1989
Aug;109(2):927e37.
8. Screaton GR, Bell MV, Bell JI, Jackson DG. The identiﬁcation of
a new alternative exon with highly restricted tissue expression
in transcripts encoding the mouse Pgp-1 (CD44) homing
receptor. Comparison of all 10 variable exons between mouse,
human, and rat. J Biol Chem 1993 Jun 15;268(17):12235e8.
9. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI.
Genomic structure of DNA encoding the lymphocyte homing
receptor CD44 reveals at least 12 alternatively spliced exons.
Proc Natl Acad Sci U S A 1992 Dec 15;89(24):12160e4.
10. Stamenkovic I, Aruffo A, Amiot M, Seed B. The hematopoietic
and epithelial forms of CD44 are distinct polypeptides with
different adhesion potentials for hyaluronate-bearing cells.
EMBO J 1991 Feb;10(2):343e8.
11. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44
is the principal cell surface receptor for hyaluronate. Cell 1990
Jun 29;61(7):1303e13.
12. St John T, Meyer J, Idzerda R, Gallatin WM. Expression of CD44
confers a new adhesive phenotype on transfected cells. Cell
1990 Jan 12;60(1):45e52.
13. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion mole-
cules to signalling regulators. Nat Rev Mol Cell Biol 2003 Jan;4
(1):33e45.
14. Marhaba R, Zoller M. CD44 in cancer progression: adhesion,
migration and growth regulation. J Mol Histol 2004 Mar;35
(3):211e31.
15. Christ O, Gunthert U, Schmidt DS, Zoller M. Allogeneic recon-
stitution after nonmyeloablative conditioning: mitigation
of graft-versus-host and host-versus-graft reactivity by
anti-CD44v6. J Leukoc Biol 2002 Jan;71(1):33e46.
16. Gunthert U, Hofmann M, Rudy W, Reber S, Zoller M,
Haussmann I, et al. A new variant of glycoprotein CD44 confers
metastatic potential to rat carcinoma cells. Cell 1991 Apr 5;65
(1):13e24.
17. Kahara N, Ozaki T, Doi T, Nishida K, Kawai A, Shibahara M, et al.
CD44 expression in soft tissue sarcomas. Virchows Arch 2000
Jun;436(6):574e8.18. Noordzij MA, van Steenbrugge GJ, Verkaik NS, Schroder FH,
van der Kwast TH. The prognostic value of CD44 isoforms in
prostate cancer patients treated by radical prostatectomy. Clin
Cancer Res 1997 May;3(5):805e15.
19. Dall P, Heider KH, Hekele A, von Minckwitz G, Kaufmann M,
Ponta H, et al. Surface protein expression and messenger
RNA-splicing analysis of CD44 in uterine cervical cancer and
normal cervical epithelium. Cancer Res 1994 Jul 1;54(13):
3337e41.
20. Heider KH, Dammrich J, Skroch-Angel P, Muller-
Hermelink HK, Vollmers HP, Herrlich P, et al. Differential
expression of CD44 splice variants in intestinal- and diffuse-
type human gastric carcinomas and normal gastric mucosa.
Cancer Res 1993 Sep 15;53(18):4197e203.
21. Joensuu H, Klemi PJ, Toikkanen S, Jalkanen S. Glycoprotein
CD44 expression and its association with survival in breast
cancer. Am J Pathol 1993 Sep;143(3):867e74.
22. Joensuu H, Ristamaki R, Klemi PJ, Jalkanen S. Lymphocyte
homing receptor (CD44) expression is associated with poor
prognosis in gastrointestinal lymphoma. Br J Cancer 1993
Aug;68(2):428e32.
23. Kuppner MC, Van Meir E, Gauthier T, Hamou MF, de Tribolet N.
Differential expression of the CD44 molecule in human brain
tumours. Int J Cancer 1992 Feb 20;50(4):572e7.
24. WashimiO,UedaR,AriyoshiY,SuyamaM,Seki T, TakahashiT, etal.
ExpressionofCD44variant isoforms innormal andneoplastic cells
of the lung. Jpn J Cancer Res 1994 Nov;85(11):1112e6.
25. Washington K, Gottfried MR, Telen MJ. Expression of the cell
adhesion molecule CD44 in gastric adenocarcinomas. Hum
Pathol 1994 Oct;25(10):1043e9.
26. Tanabe KK, Ellis LM, Saya H. Expression of CD44R1 adhesion
molecule in colon carcinomas and metastases. Lancet 1993
Mar 20;341(8847):725e6.
27. Terpe HJ, Koopmann R, Imhof BA, Gunthert U. Expression of
integrins and CD44 isoforms in non-Hodgkin's lymphomas: CD44
variant isoforms are preferentially expressed in high-grade
malignant lymphomas. J Pathol 1994 Oct;174(2):89e100.
28. Wielenga VJ, Heider KH, Offerhaus GJ, Adolf GR, van den
Berg FM, Ponta H, et al. Expression of CD44 variant proteins in
human colorectal cancer is related to tumor progression.
Cancer Res 1993 Oct 15;53(20):4754e6.
29. Kim HS, Park YB, Oh JH, Jeong J, Kim CJ, Lee SH. Expression of
CD44 isoforms correlates with the metastatic potential of
osteosarcoma. Clin Orthop Relat Res 2002 Mar;396:184e90.
30. Kuryu M, Ozaki T, Nishida K, Shibahara M, Kawai A, Inoue H.
Expression of CD44 variants in osteosarcoma. J Cancer Res Clin
Oncol 1999 Nov;125(11):646e52.
31. Bosch PP, Stevens JW, Noonan KJ, Buckwalter JA, Midura RJ.
Expression of CD44 in human neoplastic and normal hyaline
cartilage. Iowa Orthop J 2002;22:47e54.
32. EndoM,Matsumura T, Yamaguchi T, Yamaguchi U,Morimoto Y,
Nakatani F, et al. Cyclooxygenase-2 overexpression associated
with a poor prognosis in chondrosarcomas. Hum Pathol 2006
Apr;37(4):471e6.
33. Tibesku CO, Szuwart T, Ocken SA, Skwara A, Fuchs S. Increase
in the expression of the transmembrane surface receptor
CD44v6 on chondrocytes in animals with osteoarthritis.
Arthritis Rheum 2005 Mar;52(3):810e7.
34. Tibesku CO, Szuwart T, Ocken SA, Skwara A, Fuchs S. Expres-
sion of the matrix receptor CD44v5 on chondrocytes changes
with osteoarthritis: an experimental investigation in the
rabbit. Ann Rheum Dis 2006 Jan;65(1):105e8.
35. NakamuraH,KatoR,HirataA, InoueM, YamamotoT. Localization
of CD44 (hyaluronan receptor) andhyaluronan in ratmandibular
condyle. J Histochem Cytochem 2005 Jan;53(1):113e20.
T.J. Heyse et al. / Osteoarthritis and Cartilage 18 (2010) 849e85685636. Ostergaard K, Salter DM, Andersen CB, Petersen J, Bendtzen K.
CD44 expression is up-regulated in the deep zone of osteo-
arthritic cartilage from human femoral heads. Histopathology
1997 Nov;31(5):451e9.
37. AlbrechtC, SchlegelW,Eckl P, JagersbergerT, SadeghiK,BergerA,
et al. Alterations in CD44 isoforms andHAS expression in human
articular chondrocytes during the de- and re-differentiation
processes. Int J Mol Med 2009 Feb;23(2):253e9.
38. Knudson W, Aguiar DJ, Hua Q, Knudson CB. CD44-anchored
hyaluronan-rich pericellular matrices: an ultrastructural and
biochemical analysis. Exp Cell Res 1996 Nov 1;228(2):216e28.
39. Ishida O, Tanaka Y, Morimoto I, Takigawa M, Eto S.
Chondrocytes are regulated by cellular adhesion through CD44
and hyaluronic acid pathway. J Bone Miner Res 1997 Oct;12
(10):1657e63.
40. Yoshida M, Yasuda T, Hiramitsu T, Ito H, Nakamura T. Induction
of apoptosis by anti-CD44 antibody in human chondrosarcoma
cell line SW1353. Biomed Res 2008 Feb;29(1):47e52.
41. Kobayashi H, Suzuki M, Kanayama N, Nishida T, Takigawa M,
Terao T. CD44 stimulation by fragmented hyaluronic acid
induces upregulation of urokinase-type plasminogen activator
and its receptor and subsequently facilitates invasion of human
chondrosarcoma cells. Int J Cancer 2002 Dec 1;102(4):379e89.
42. Fiorenza F, Abudu A, Grimer RJ, Carter SR, Tillman RM,
Ayoub K, et al. Risk factors for survival and local control in
chondrosarcoma of bone. J Bone Joint Surg Br 2002 Jan;84
(1):93e9.
43. Kaufmann M, Heider KH, Sinn HP, von Minckwitz G, Ponta H,
Herrlich P. CD44 variant exon epitopes in primary breastcancer and length of survival. Lancet 1995 Mar 11;345
(8950):615e9.
44. Friedrichs K, Franke F, Lisboa BW, Kugler G, Gille I, Terpe HJ,
et al. CD44 isoforms correlate with cellular differentiation but
not with prognosis in human breast cancer. Cancer Res 1995
Nov 15;55(22):5424e33.
45. Bhatavdekar JM, Patel DD, Chikhlikar PR, Trivedi TI,
Gosalia NM, Ghosh N, et al. Overexpression of CD44: a useful
independent predictor of prognosis in patients with colorectal
carcinomas. Ann Surg Oncol 1998 Sep;5(6):495e501.
46. Lipponen P, Aaltoma S, Kosma VM, Ala-Opas M, Eskelinen M.
Expression of CD44 standard and variant-v6 proteins in tran-
sitional cell bladder tumours and their relation to prognosis
during a long-term follow-up. J Pathol 1998 Oct;186
(2):157e64.
47. Bottger TC, Youssef V, Dutkowski P, Maschek H, Brenner W,
Junginger T. Expression of CD44 variant proteins in adeno-
carcinoma of Barrett's esophagus and its relation to prognosis.
Cancer 1998 Sep 15;83(6):1074e80.
48. Fujita N, Yaegashi N, Ide Y, Sato S, Nakamura M, Ishiwata I,
et al. Expression of CD44 in normal human versus tumor
endometrial tissues: possible implication of reduced expres-
sion of CD44 in lymph-vascular space involvement of cancer
cells. Cancer Res 1994 Jul 15;54(14):3922e8.
49. Salles G, Zain M, Jiang WM, Boussiotis VA, Shipp MA. Alter-
natively spliced CD44 transcripts in diffuse large-cell
lymphomas: characterization and comparison with normal
activated B cells and epithelial malignancies. Blood 1993 Dec
15;82(12):3539e47.
